Sandu Pharmaceuticals Ltd. (BSE: 524703) is a Mumbai, Maharashtra-based company in the Vitamins and Nutritional Supplements industry. With a market capitalisation of ₹37 Cr, it ranks #4,016 by market cap among the 6,197 Indian listed companies on FinBizNet, and #3 of 5 in Vitamins and Nutritional Supplements. At ₹37.50 (as of 16 Nov 2026), the share price is 25.0% below its 52-week high of ₹50.00 and 25.0% above its 52-week low of ₹30.00. The share price is down 12.8% over one year and up 3.4% over three months.
| Current Price | ₹37.50 |
|---|---|
| Market Cap | ₹37 Cr |
| BSE Code | 524703 |
| Sector | Consumer Staples > Household and Personal Products > Personal Care Products |
| Sub-Industry | Personal Care Products > Vitamins and Nutritional Supplements |
| P/E Ratio | 20.7 |
| Return on Equity | 4.13% |
| Return on Assets | 2.60% |
| 52-Week Range | ₹30.00 – ₹50.00 |
| 1-Year Price Change | -12.8% |
| 3-Month Price Change | +3.4% |
| Beta (1Y) | 0.47 |
| Dividend Yield | 2.64% |
| Headquarters | Mumbai, Maharashtra |
| Website | sandu.in |
| Revenue | ₹16 Cr |
|---|---|
| Net Profit | ₹0 Cr |
| Net Margin | 1.4% |
| EPS (Basic) | ₹0.37 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Sandu Pharmaceuticals Ltd. reported revenue of ₹16 Cr in Q1 FY27, down 1.9% from ₹17 Cr in Q1 FY26 and down 2.7% from ₹17 Cr in Q4 FY26. It posted a net profit of ₹0 Cr for the quarter, against a net profit of ₹0 Cr in Q1 FY26 (up 4.5%). Across the 8 quarters from Q2 FY25 to Q1 FY27, quarterly revenue ranged from ₹14 Cr (Q4 FY25) to ₹19 Cr (Q3 FY26). The company was profitable in each of these 8 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q1 FY27 | ₹16 Cr | ₹0 Cr | 1.4% |
| Q4 FY26 | ₹17 Cr | ₹0 Cr | 0.2% |
| Q3 FY26 | ₹19 Cr | ₹1 Cr | 5.2% |
| Q2 FY26 | ₹18 Cr | ₹1 Cr | 3.0% |
| Q1 FY26 | ₹17 Cr | ₹0 Cr | 1.3% |
| Q4 FY25 | ₹14 Cr | ₹0 Cr | 2.3% |
| Q3 FY25 | ₹18 Cr | ₹1 Cr | 3.0% |
| Q2 FY25 | ₹18 Cr | ₹1 Cr | 2.8% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 74.22% of Sandu Pharmaceuticals Ltd.'s shares as of Mar 2026, unchanged from Mar 2025. Delivery averaged 83.7% of traded volume across 14 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Sandu Pharmaceuticals Limited manufactures and sells ayurvedic medicines under the SANDU brand in India and internationally. It offers sandu mahasudarshan kadha no 1, sandu abhayarishta, sandu pathyadi kadha, sandu makarprash, sandu gulkand pravalyukta, sandu acivin herbal antacid, sandu ashwagandharishta, sandu amritarishta, sandu hemocleen excellent blood purifier, and sandu vanari granules. The company also provides mahasudarshan kadha, amritarishta, tab. samshamani vati, pathajeevani, vasa cough syrup, whoopin syrup, somajeevani, drakshasava, stressan, ashwagandharishtam, sandu sitopalasava, makarprash, chyavanprash, and ayush kwath. Sandu Pharmaceuticals Limited was founded in 1899 and is based in Mumbai, India.
1. Ayurvedic Property Medicines-This segment engages in the manufacture and marketing of ayurvedic medicines.
1. Ayurvedic Property Medicines-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Hexagon Nutrition Limited | ₹737 Cr | 19.4 | 16.26% | ₹110 Cr | — |
| Aayush Food And Herbs Ltd | ₹144 Cr | 36.4 | 38.75% | — | -67.8% |
| Sandu Pharmaceuticals Ltd. | ₹37 Cr | 20.7 | 4.13% | ₹16 Cr | -12.8% |
| Deccan Health Care Ltd | ₹28 Cr | 11.9 | 2.11% | ₹22 Cr | -30.1% |
| Walpar Nutritions Limited | ₹23 Cr | 9.2 | 13.93% | — | -47.4% |
Listed by market capitalisation. Ratios are shown for context only.
Sandu Pharmaceuticals Ltd. is trading at ₹37.50, with a market capitalisation of ₹37 Cr.
Sandu Pharmaceuticals Ltd. operates in the Consumer Staples > Household and Personal Products > Personal Care Products space (Personal Care Products > Vitamins and Nutritional Supplements).
Sandu Pharmaceuticals Ltd. has a P/E of 20.7 and a return on equity of 4.13%.
Sandu Pharmaceuticals Ltd. is listed on the BSE under the scrip code 524703.
Sandu Pharmaceuticals Ltd.'s share price is down 12.8% over one year and up 3.4% over three months. Its 52-week range is ₹30.00 to ₹50.00.
In Q1 FY27, Sandu Pharmaceuticals Ltd. reported revenue of ₹16 Cr and net profit of ₹0 Cr, with basic EPS of ₹0.37 (standalone, parsed from the company's exchange filing).
Sandu Pharmaceuticals Ltd. reported revenue of ₹16 Cr in Q1 FY27, down 1.9% from ₹17 Cr in Q1 FY26 and down 2.7% from ₹17 Cr in Q4 FY26.
Promoters held 74.22% of Sandu Pharmaceuticals Ltd.'s shares as of Mar 2026, unchanged from Mar 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.